Nvidia is making a bigger bet on using artificial intelligence to speed up drug development, and this time it's bringing two smaller players along for the ride.

The chip giant announced separate initiatives Tuesday with Certara (CERT) and Silo Pharma (SILO) that aim to weave AI agents into the fabric of pharmaceutical research. Certara is integrating Nvidia's BioNeMo Agent Toolkit into its AI-driven drug development platform, while Silo Pharma's subsidiary, QwikAgents, has joined the Nvidia Developer Program to strengthen its own AI agent capabilities.

Nvidia stock was gaining traction on the news, continuing a positive trend.

Certara Integrates Nvidia BioNeMo Into AI Drug Development Platform

Certara said it is partnering with Nvidia to advance its open, integrated AI platform by combining its scientific software, regulatory expertise, and proprietary datasets with AI-first, agentic frameworks. Under the collaboration, the Nvidia BioNeMo Agent Toolkit will become one of several agentic frameworks available within Certara's platform.

The toolkit is designed to turn AI agents into autonomous life sciences researchers by providing access to Nvidia's life sciences technology stack while complementing Certara's biosimulation models, regulatory expertise and scientific teams.

AI Agents Target Drug Development Workflows

According to Certara, specialized AI agents will analyze scientific models, datasets and domain expertise across multiple stages of drug development. The company said these agents can support tasks such as optimizing dosing strategies using systems pharmacology models, analyzing clinical datasets, simulating patient and clinical trial scenarios, evaluating ADMET properties, assembling regulatory-ready evidence and assessing early-stage drug discovery hypotheses.

Certara added that the technology is intended to enhance the work of biosimulation experts and scientific teams by accelerating insight generation while keeping scientists at the center of decision-making.

Silo Pharma Subsidiary Joins Nvidia Developer Program

Separately, Silo Pharma announced its wholly owned subsidiary, QwikAgents, has joined the Nvidia Developer Program. The company said QwikAgents' platform automates complex workflows using autonomous AI agents capable of reasoning, taking action and interacting with enterprise systems. The platform also incorporates persistent memory, intelligent routing across multiple large language model providers, browser automation and secure data management to support scalable AI-driven operations.

Silo Pharma said participation in the Nvidia Developer Program will provide QwikAgents with access to Nvidia's AI software ecosystem, development frameworks, technical training and optimization resources. The company expects those resources to help accelerate platform enhancements as it expands AI agent capabilities for enterprise customers.

Stock Price Activity: Certara shares were down 0.63% at $7.09, Silo Pharma shares were down 2.10% at $6.09 at the time of publication on Tuesday, according to market data.